{"id":3765,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2018-06-21","marketCap":240.337,"name":"Xeris Biopharma Holdings Inc","phone":"18444455704.0","outstanding":138.07,"symbol":"XERS","website":"https://www.xerispharma.com/","industry":"Pharmaceuticals"},"price":2.29,"year":2024,"month":6,"day":12,"weekday":"Wednesday","title":"The Impact of Natural Disasters and Climate-Related Risks on Xeris Biopharma Holdings Inc Stock and its Industry","date":"2024-06-12","url":"/posts/2024/06/12/XERS","content":[{"section":"Supply Chain Disruptions","text":"Natural disasters such as hurricanes, floods, and wildfires can cause disruptions in Xeris Biopharma Holdings Inc's supply chain. These events can damage manufacturing facilities, interrupt transportation routes, and hinder the availability of raw materials. As a result, the company may experience delays in production or face difficulties in meeting customer demands. This can negatively affect stock performance as investors may perceive supply chain disruptions as a sign of instability and increased operational risk."},{"section":"Infrastructure Damage","text":"The infrastructure required for pharmaceutical manufacturing and distribution can be vulnerable to natural disasters and climate-related risks. Infrastructure damage, including power outages, can impact Xeris Biopharma Holdings Inc's ability to operate efficiently. For example, if a manufacturing facility is unable to maintain ideal storage conditions for sensitive drugs due to power disruptions caused by severe weather events, it can lead to product spoilage or quality issues. Consequently, stock performance may suffer due to increased costs, operational setbacks, and potential reputational damage."},{"section":"Increased Costs","text":"Natural disasters and climate-related risks can give rise to increased costs for Xeris Biopharma Holdings Inc and its industry. For instance, the need to implement disaster preparedness measures, such as enhancing facility resilience, backup power systems, and security protocols, can require significant investments. Additionally, insurance premiums may rise for companies operating in disaster-prone areas. These increased costs can impact profit margins and investor confidence, potentially resulting in a decline in stock value."},{"section":"Mitigating Risks through Climate Resilience","text":"To manage the impact of natural disasters and climate-related risks, Xeris Biopharma Holdings Inc can prioritize climate resilience. This involves adopting strategies and technologies to minimize vulnerabilities and improve the company's ability to withstand and recover from adverse events. For example, implementing backup power systems, securing alternative sources of raw materials, and diversifying manufacturing locations can enhance supply chain resilience. Investing in sustainable and energy-efficient infrastructure can also reduce the company's environmental footprint and enhance operational efficiency. By demonstrating a commitment to climate resilience, Xeris Biopharma Holdings Inc can improve its long-term prospects and potentially attract environmentally conscious investors."},{"section":"Industry-wide Impact","text":"Natural disasters and climate-related risks can affect the pharmaceutical industry as a whole, not just Xeris Biopharma Holdings Inc. Industry-wide disruptions can impact the availability of drugs, leading to potential shortages and increased prices. This can create challenges for companies across the supply chain, including manufacturers, wholesalers, and retailers. Consequently, investor sentiment towards the entire industry may be dampened, leading to a decline in stock values. Therefore, it is essential for the pharmaceutical industry to collaborate and invest in climate resilience to mitigate these risks collectively."}],"tags":["CrossOver21","Long","Pharmaceuticals"],"news":[{"category":"company","date":1718107725,"headline":"Corcept Therapeutics Stock Merits Accumulation","id":128199696,"image":"","symbol":"XERS","publisher":"SeekingAlpha","summary":"","url":"https://seekingalpha.com/article/4698637-corcept-therapeutics-stock-merits-accumulation"},{"category":"company","date":1717679486,"headline":"Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit","id":128134463,"image":"https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","symbol":"XERS","publisher":"Yahoo","summary":"We feel now is a pretty good time to analyse Xeris Biopharma Holdings, Inc.'s ( NASDAQ:XERS ) business as it appears...","url":"https://finance.yahoo.com/news/xeris-biopharma-holdings-inc-nasdaq-131126789.html"},{"category":"company","date":1717560240,"headline":"Xeris Pharmaceuticals Shareholders Back Key Proposals and Directors","id":128125563,"image":"","symbol":"XERS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3528070206"},{"category":"company","date":1717471860,"headline":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Xeris Pharmaceuticals (XERS) and Bristol-Myers Squibb (BMY)","id":128070047,"image":"","symbol":"XERS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3525556012"},{"category":"company","date":1717412400,"headline":"Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024","id":128045752,"image":"https://media.zenfs.com/en/business-wire.com/bd0650f730f26d8955f11ae3436d9dc5","symbol":"XERS","publisher":"Yahoo","summary":"CHICAGO, June 03, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced it presented a post-hoc analysis from its previously published SONICS study on the effects of levoketoconazole (Recorlev®) in adults with Cushing’s syndrome at ENDO 2024 in Boston, June 1-4, 2024.","url":"https://finance.yahoo.com/news/xeris-presents-post-hoc-analysis-110000088.html"},{"category":"company","date":1717395960,"headline":"Xeris presents data on SONICS study on effects of levoketoconazole on CS","id":128050093,"image":"","symbol":"XERS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3523949787"},{"category":"company","date":1717138260,"headline":"Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS) and Gilead Sciences (GILD)","id":128006982,"image":"","symbol":"XERS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3520419594"},{"category":"company","date":1717132860,"headline":"Analysts’ Top Healthcare Picks: Phreesia (PHR), Xeris Pharmaceuticals (XERS)","id":128005538,"image":"","symbol":"XERS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3520336707"},{"category":"company","date":1717069020,"headline":"12 Health Care Stocks Moving In Thursday's Intraday Session","id":127975662,"image":"","symbol":"XERS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3518913009"},{"category":"company","date":1717068600,"headline":"Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)","id":127973856,"image":"https://media.zenfs.com/en/business-wire.com/25454dc35b7a422551f731dffd446d7c","symbol":"XERS","publisher":"Yahoo","summary":"CHICAGO, May 30, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company’s XeriSol™ formulation technology to enable a novel once-weekly SC injection","url":"https://finance.yahoo.com/news/xeris-biopharma-announces-positive-topline-113000409.html"},{"category":"company","date":1717066800,"headline":"Xeris to Participate in the Jefferies Global Healthcare Conference","id":127973857,"image":"https://media.zenfs.com/en/business-wire.com/3bcc7d405fdff063b253340d74bd5dc0","symbol":"XERS","publisher":"Yahoo","summary":"CHICAGO, May 30, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6 at 2:00pm Eastern Time.","url":"https://finance.yahoo.com/news/xeris-participate-jefferies-global-healthcare-110000972.html"},{"category":"company","date":1717066500,"headline":"What You Missed On Wall Street This Morning","id":127974394,"image":"","symbol":"XERS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3518851011"},{"category":"company","date":1717061580,"headline":"Xeris stock jumps 14% on Phase 2 data for injected levothyroxine","id":127975917,"image":"","symbol":"XERS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3518734789"},{"category":"company","date":1717056480,"headline":"Xeris Pharmaceuticals (XERS) Gets a Buy from Craig-Hallum","id":127975918,"image":"","symbol":"XERS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3518619007"},{"category":"company","date":1717051080,"headline":"Xeris announces XeriSol data formulated once-weekly SC levothyroxine","id":127975921,"image":"","symbol":"XERS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3518513359"},{"category":"company","date":1717040160,"headline":"What You Missed On Wall Street On Thursday","id":127981740,"image":"","symbol":"XERS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3519276935"}]}